Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VGN-R08b in Parkinson's Disease with GBA1 Mutations
NCT07414290Phase 2Not yet recruiting
- Sponsor
- Shanghai Vitalgen BioPharma Co., Ltd.
- Start
- May 2026
- Primary completion
- Sep 2027
- Modality
- Gene Editing, Gene Silencing, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of VGN-R08b in Parkinson's disease (PD), sponsored by Shanghai Vitalgen BioPharma Co., Ltd.. Planned start May 2026; status: not yet recruiting.
02
Drugs
VGN-R08b
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07414290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07414290.